In order to compare the clinical and microbiological efficacies and safety of piperacillin plus tazobactam with those of imipenem plus cilastatin, 134 patients with intra-abdominal infections ( (11, 14) .
in the imipenem-cilastatin group were clinically cured. The differences were significant (Wilcoxon test; P = 0.005). There were 4 failures or relapses in the piperacillin-tazobactam group and 18 failures or relapses in the imipenem-cilastatin group. The microorganisms isolated were eradicated in similar proportions in the two patient groups. Adverse reactions, mainly gastrointestinal disturbances and nausea, were noted in 13 patients who received piperacillin-tazobactam and in 14 patients who received imipenem-cilastatin. Results of the present study show that piperacillin-tazobactam is effective and safe for the treatment of intra-abdominal infections.
The treatment of intra-abdominal infections requires surgical intervention together with antibiotic therapy. These infections, caused by the endogenous intestinal microflora, are usually polymicrobial and involve both gram-positive and gram-negative aerobic and anaerobic bacteria. The most often isolated aerobic bacteria are enterococci and enterobacteria. Among the anaerobic bacteria, Bacteroides fragilis, clostridia, and anaerobic cocci are the most commonly recovered. Antibiotics used for therapy of these infections must be active against both the aerobic and anaerobic bacteria of intestinal origin. For a long time, aminoglycosides in combination with clindamycin or metronidazole have been the most common antibiotic regimen. Other combinations as well as single broad-spectrum agents have also been used. Imipenem-cilastatin as a single agent has been thoroughly investigated and successfully used for the treatment of intra-abdominal infections (11, 14) .
Tazobactam is a newly developed P-lactamase inhibitor of the penicillanic acid sulfone class. Its structure is similar to that of sulbactam, except that one of the methyl groups of sulbactam is replaced by a triazolylmethyl group. It is more active than sulbactam against enterobacteria that produce class III and V plasmid-mediated 3-lactamases and is more active than clavulanic acid against those that produce class I chromosomal 3-lactamases (2, 7, 9) .
Piperacillin is an extended-spectrum penicillin which has been widely used in the treatment of serious infections. It is active against most enterobacteria and also shows good activity against enterococci and most anaerobic bacteria (5) .
Recently, the spread of 3-lactamase-producing organisms has raised concerns about the future utility of piperacillin and suggested that it should be used in combination with a 1-lactamase inhibitor such as tazobactam. In vitro studies have shown that piperacillin plus tazobactam is one of the most active penicillin-inhibitor combinations against a wide variety of resistant gram-negative aerobic and anaerobic bacteria (7, 9 known allergy to beta-lactam antibiotics and 1-lactamase inhibitors; patients infected with microorganisms which were known to be resistant to piperacillin-tazobactam or imipenem-cilastatin; patients in septic shock; patients treated with probenecid; patients on another investigational drug; patients on another antimicrobial agent within the past 72 h; patients with impaired renal or hepatic function, patients with serum transaminases, alkaline phosphatase, or bilirubin greater than or equal to three times the upper normal limit; patients with central nervous system disorders; and patients with concomitant infection other than intraabdominal infection.
The investigators met before and several times during the investigation to coordinate and evaluate the results. The final clinical and microbiological outcomes were evaluated and determined blinded by the scientific coordinators (A.E.E. and C.E.N.). The code was broken for the two blinded evaluators when all patients had completed the trial. The design of the trial was approved by the Ethics Review Committee of the Karolinska Institute, Stockholm, and the National Board of Health, Uppsala.
Criteria for clinical and microbiological evaluability. Criteria for clinical evaluability were (i) the existence of a clinically proven infection, i.e., visible pus found in the abdomen at laparotomy or obtained from aspiration of an abscess, or the occurrence of an intestinal perforation with frank peritonitis, (ii) the completion of a treatment course of at least 3 days, (iii) and two follow-up visits 1 to 2 and 4 to 6 weeks after the completion of treatment. The patients were evaluated for clinical efficacies of their treatments as follows: (i) cure, the patient was asymptomatic with no evidence of infection at the time that treatment was completed and at the posttherapy evaluation; (ii) improvement, significant improvement of symptoms on evaluation at the end of therapy or at the posttherapy evaluation but without complete resolution of evidence of infection; (iii) relapse, clinical improvement followed by deterioration during therapy or at the posttreatment evaluation; and (iv) failure, no demonstrable response to therapy.
Criteria for microbiological evaluability were that the patient was clinically evaluable and that at least one microorganism that was susceptible to the test drugs was isolated from the site of infection before the start of antibiotic treatment.
In addition to analyzing the clinically and microbiologically evaluable patients, who were determined by the blinded evaluators, an analysis of all patients who were entered into the study and all patients for whom an evaluation was made by the treating surgeon was performed. This intent-to-treat analysis allowed a judgment of outcome to be made for empiric therapy which is encountered in normal patient care.
Antibiotic treatment. The patients randomized to the piperacillin-tazobactam group received 4 g of piperacillin and 500 mg of tazobactam every 8 h by intravenous infusion over 30 min. Patients in the imipenem-cilastatin group received imipenem and cilastatin at dosages of 500 mg of each drug every 8 h as a 30-min intravenous infusion. The imipenemcilastatin doses of 500 mg each every 8 h is the usually recommended dose in Scandinavia for the treatment of moderate infections and has previously been demonstrated to be efficacious in prospective comparative trials (6, 12, 16) ; this differs from the usual dose of 500 mg every 6 h used in North America (8, 13, 14) . The recommended dose range for imipenem-cilastatin is 0.75 to 4 g of each drug per day. The minimum duration of antibiotic treatment was 3 days.
Microbiological investigations. Before the administration of the antibiotics, two sets of aerobic and anaerobic blood culture samples were obtained by venipunctures at least 5 min apart. Cultures for aerobic and anaerobic bacteria from other infected sites, i.e., pus, aspirate, and wound, were also taken before the start of antibiotic treatment. Follow-up blood cultures and specimens from primary infected sites were taken, if possible, during and after antibiotic treatment. Standard antibiotic disc susceptibility tests of piperacillin, piperacillin-tazobactam, and imipenem were carried out on the isolated bacteria. All isolated strains were stored on deep agar and were sent to the coordinating central microbiological laboratory (National Bacteriological Laboratory, Stockholm), where MICs were determined by the agar dilution technique (3). The following breakpoints were used for classification of the isolates as susceptible or resistant: for piperacillin, susceptible, <8 mg/liter; resistant, 232 mg/liter; for piperacillin plus tazobactam, susceptible, <8 mg/liter; resistant, 232 mg/liter; for imipenem, susceptible, <4 mg/ liter; resistant, 216 mg/liter. 3-Lactamase production was tested with nitrocefin.
Clinical laboratory tests. The following laboratory tests were carried out before, during, and after the end of therapy: hemoglobin, hematocrit, total and differential leukocyte counts, platelet counts, protrombin time, serum creatinine, serum urea, serum alkaline phosphate, serum bilirubin, serum lactic dehydrogenase, glucose, sodium, potassium, calcium, and urinalysis.
Statistical methods. All tests for statistical significance of treatment difference were performed at a two-sided level of significance of 8 = 0.05. Statistical analysis was applied to each subset of data by using two methods of analysis. The distribution of ordered categorical data (patient-level clinical and microbiological responses and severity of adverse experiences) were compared nonparametrically between the two treatment groups by the two-sided Wilcoxon rank sum test. The chi-square test was used to compare the favorable response rates between the two treatment groups. If any expected cell count was five or less, a two-sided Fisher's exact test was used. Fisher's exact test calculates the cumulative probability of all events which are as extreme or more extreme than that observed (1). RESULTS One hundred thirty-four patients were entered into the trial; 69 patients were in the piperacillin-tazobactam group and 65 patients were in the imipenem-cilastatin group. There were 40 men and 29 women (mean age, 52.9 years; age range, 18 to 92 years) in the piperacillin-tazobactam group and 40 men and 25 women (mean age, 54.0 years; age range, 16 to 91 years) in the imipenem-cilastatin group. The demographic characteristics for the patients are given in Table 1 . All clinically and microbiologically evaluable patients enrolled in each treatment group were similar with respect to sex, race, age, height (range, 148 to 197 cm; mean height, 172.3 cm), and weight (range, 45 to 121 kg; mean weight, 74.1 kg). The distribution of patients by disease indication is presented in Table 2 . The most common clinical diagnoses were complicated appendicitis (frank perforation, gangrenous with positive intra-abdominal culture), peritonitis, and intraabdominal abscesses and were similar among patients in both treatment groups. Surgical therapy was similar for patients in each group (data not shown).
Evaluation of clinical outcome. One hundred thirteen patients met the criteria for clinical evaluability (Table 3) . (Table   3 ). The differences were statistically significant (Wilcoxon test; P = 0.005). The clinical responses in the microbiologically evaluable patients are also given in Table 3 . Among 41 patients in the piperacillin-tazobactam group, 38 patients were cured or improved, while 3 patients had relapses or failures. Thirty-six patients in the imipenem-cilastatin group were cured and 13 patients showed no improvement (Wilcoxon test; P = 0.052).
Evaluation of alf patiens by intent to treat. Of the 134 patients entered into the study, a follow-up evaluation to determine outcome was done for 127 of them (Table 5 ). Rank order analysis of the outcomes in the two groups showed a statistically significant difference in favor of piperacillintazobactam (Wilcoxon test; P = 0.005) ( Table 5) . When considering the favorable response rate, which includes the cured and improved patients, as shown in Table 5 , there was a significant difference in favor of piperacillin-tazobactam treatment (chi-square test; P = G.003). The final analysis that included all randomized patients is presented in Table 5 . In this analysis, patients for whom there was no follow-up, which included five in the piperacillin-tazobactam group and two in the imipenem-cilastatin group, were classified as failures. The statistical evaluation revealed a signiicat difference in the outcome in favor of piperacillin-tazobactam (chi-square test; P = 0.022). Thus, the analysis of intent to treat confirmed a statistical superiority of the efficacy of piperacillin-tazobactam over that of imipenem-cilastatin at the dosages used in the present study.
Evaluation of microbilgicl outcome. Ninety patients were microbiologically evaluable according to the criteria given above (Table 6 ). There were 41 evaluable patients in the piperaciflin-tazobactam group and 49 in the imipenemcilastatin group. In the piperacillin-tazobactam group, the bacteria were eradicated from 38 patients but the microorganisms persisted in 3 patients, whereas in the imipenemcilastatin group, eradication was recorded in 37 patients, 2 patients developed superinfection, 1 patient had a reinfection, and 9 patients had persisting microorganisms. The differences between the groups were in favor of piperacillintazobactam (Wilcoxon test; P = 0.036). Piperacillin-resistant, piperacillin-tazobactam-susceptible microorganisms were isolated from 26 patients treated with piperacillintazobactam and 29 patients treated with imipenem-cilastatin. In the piperacillin-tazobactam group, the bacteria were eradicated from 24 patients and 2 patients showed persistence of microorganisms, while the bacteria were eradicated from 23 patients in the imipenem-cilastatin group, 1 patient developed a reinfection, and 5 5-072) in the imipenem-cilastatin group had enterococcal superinfections with susceptible organisms. Two hundred seventy aerobic and 164 anaerobic bacterial strains were isolated. Escherichia coli predominated among the aerobic bacteria and Bacteroides fragilis predominated among the anaerobic bacteria. Among the aerobic bacteria, 19 isolates were resistant to piperacillin-tazobactam and 11 isolates were resistant to imipenem-cilastatin (Table 8) . One hundred fifty-four of the aerobic strains (57%) were 1-lactamase producers, and 121 of the anaerobic strains (74%) were 3-lactamase producers. On the basis of the MIC breakpoint for these two different drugs and the susceptibilities of the pathogens encountered in the study of patients with intra- abdominal infections, the in vitro activity of the piperacillintazobactam is similar to that of imipenem. The microorganisms that caused treatment failures or relapses in the piperacillin-tazobactam group were Escherichia coli and Bacteroides fragilis; those in the imipenem-cilastatin group were Enterococcus faecalis, Enterococcus faecium, Streptococcus milleri, Streptococcus intermedius, Streptococcus mitior, Streptococcus mutans, Lactobacillus sp., Escherichia coli, Proteus rettgeri, Haemophilus influenzae, Peptostreptococcus micros, Bacteroides distasonis, Bacteroides fragilis, and Bacteroides vulgatus. These organisms were susceptible to the study drugs. Adverse reactions. Adverse reactions were recorded in 13 patients in the piperacillin-tazobactam group and 14 patients in the imipenem-cilastatin group. There was no significant difference between the two treatment groups. In the piperacillin-tazobactam group, five patients had diarrhea and one patient had nausea, while in the imipenem-cilastatin group, .Q. (12, 13 Since most intraabdominal infections are polymicrobial and involve both aerobic and anaerobic bacteria, antimicrobial treatment should cover both groups of bacteria. Imipenem, broad-spectrum cephalosporins, broad-spectrum penicillins, and aminoglycosides are recommended for coverage of aerobic bacteria. The agents effective against the most important anaerobic species (Bacteroides fragilis) are imipenem, clindamycin, and metronidazole. The efficacies of different antimicrobial combinations covering both aerobic and anaerobic bacteria are now well established for the treatment of intra-abdominal infections. Antimicrobial monotherapy to cover both aerobic and anaerobic bacteria is an attractive concept in terms of simplifying the dosing schedule. The advantages of monotherapy versus combination therapy must be considered in relation to the comparative efficacies of the therapies. As reported by Kager and Nord (11) and Solomkin et al. (14) , imipenem has been useful as a single agent in the treatment of intra-abdominal infections.
Beta-lactam antibiotics in combination with 1-lactamase inhibitors have been used during recent years for the treatment of intra-abdominal infections. Ampicillin plus sulbactam has been compared with gentamicin plus clindamycin in a randomized trial for the treatment of intra-abdominal infections in surgical patients (15 The findings presented here demonstrate that piperacillintazobactam can also be considered effective and safe in the treatment of intra-abdominal infections.
